Invasive Candidiasis in Critically Ill Patients: A Prospective Cohort Study in Two Tertiary Care Centers

Hasan M Al-Dorzi, Hussam Sakkijha, Raymond Khan, Tarek Aldabbagh, Aron Toledo, Pendo Ntinika, Sameera M Al Johani, Yaseen M Arabi, Hasan M Al-Dorzi, Hussam Sakkijha, Raymond Khan, Tarek Aldabbagh, Aron Toledo, Pendo Ntinika, Sameera M Al Johani, Yaseen M Arabi

Abstract

Background: Invasive candidiasis is not uncommon in critically ill patients but has variable epidemiology and outcomes between intensive care units (ICUs). This study evaluated the epidemiology, characteristics, management, and outcomes of patients with invasive candidiasis at 6 ICUs of 2 tertiary care centers.

Methods: This was a prospective observational study of all adults admitted to 6 ICUs in 2 different hospitals between August 2012 and May 2016 and diagnosed to have invasive candidiasis by 2 intensivists according to predefined criteria. The epidemiology of isolated Candida and the characteristics, management, and outcomes of affected patients were studied. Multivariable logistic regression analyses were performed to identify the predictors of non-albicans versus albicans infection and hospital mortality.

Results: Invasive candidiasis was diagnosed in 162 (age 58.4 ± 18.9 years, 52.2% males, 82.1% medical admissions, and admission Acute Physiology and Chronic Health Evaluation II score 24.1 ± 8.4) patients at a rate of 2.6 cases per 100 ICU admissions. On the diagnosis day, the Candida score was 2.4 ± 0.9 in invasive candidiasis compared with 1.6 ± 0.9 in Candida colonization (P < .01). The most frequent species were albicans (38.3%), tropicalis (16.7%), glabrata (16%), and parapsilosis (13.6%). In patients with candidemia, antifungal therapy was started on average 1 hour before knowing the culture result (59.6% of therapy initiated after). Resistance to fluconazole, caspofungin, and amphotericin B occurred in 27.9%, 2.9%, and 3.1%, respectively. The hospital mortality was 58.6% with no difference between albicans and non-albicans infections (61.3% and 54.9%, respectively; P = .44). The independent predictors of mortality were renal replacement therapy after invasive candidiasis diagnosis (odds ratio: 5.42; 95% confidence interval: 2.16-13.56) and invasive candidiasis leading/contributing to ICU admission versus occurring during critical illness (odds ratio: 2.87; 95% confidence interval: 1.22-6.74).

Conclusions: In critically ill patients with invasive candidiasis, non-albicans was responsible for most cases, and mortality was high (58.6%). Antifungal therapy was initiated after culture results in 60% suggesting low preclinical suspicion. Study registration: NCT01490684; registered in ClinicalTrials.gov on February 11, 2012.

Keywords: antifungal agents; candidiasis; critical care outcomes; intensive care; sepsis.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Order rank of the different species of Candida causing invasive candidiasis (A) and candidemia (B) in all medical and surgical patients.
Figure 2.
Figure 2.
Serial Sequential Organ Failure Assessment Scores in survivors and nonsurvivors of patients with invasive candidiasis; P values were > .05 at all points.
Figure 3.
Figure 3.
Mortality according to the Candida species causing invasive candidiasis (A) and candidemia (B) in all medical and surgical patients.

References

    1. Laverdiere M, Labbe AC, Restieri C, et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care. 2007;22(3):245–250.
    1. van de Veerdonk FL, Kullberg BJ, Netea MG. Pathogenesis of invasive candidiasis. Curr Opin Crit Care. 2010;16(5):453–459.
    1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329.
    1. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses. 2002;45(5-6):141–145.
    1. Pfaller M, Diekema D, Gibbs D, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol.2010;48(4):1366–1377.
    1. Kaaniche FM, Allela R, Cherif S, ben Algia N. Invasive candidiasis in critically ill patients. Trend Anaesth Crit Care. 2016;11:1–5.
    1. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73–85.
    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2015;62(4):e1–e50.
    1. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Annintensive care. 2011;1(1):37.
    1. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695–1703.
    1. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27(4):781–788.
    1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41(9):1232–1239.
    1. Falagas M, Apostolou K, Pappas V. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006;25(7):419–425.
    1. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The nationalepidemiology of mycosissurvey. Clin Infect Dis. 2001;33(2):177–186.
    1. Petri MG, Konig J, Moecke HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-ehrlich society for chemotherapy, divisions of mycology and pneumonia research. Inten Care Med. 1997;23(3):317–325.
    1. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37(5):1612–1618.
    1. Al-Hedaithy SS. The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses. 2003;46(8):293–298.
    1. Osoba AO, Al-Mowallad AW, McAlear DE, Hussein BA. Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J. 2003;24(10):1060–1063.
    1. Al-Jasser AM, Elkhizzi NA. Distribution of Candida species among bloodstream isolates. Saudi Med J. 2004;25(5):566–569.
    1. Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis. 2007;11(3):239–244.
    1. Omrani AS, Makkawy EA, Baig K, et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J. 2014;35(8):821–826.
    1. Arabi Y, Alshimemeri A, Taher S. Weekend and weeknight admissions have the same outcome of weekday admissions to an intensive care unit with onsite intensivist coverage. Crit Care Med. 2006;34(3):605–611.
    1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
    1. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–1633.
    1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29(4):530–538.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.
    1. León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730–737.
    1. Aguilar G, Delgado C, Corrales I, et al. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study. BMC Res Notes. 2015;8:491.
    1. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: candida infections in the intensive care unit. Crit Care. 2008;12(1):204.
    1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370(13):1198–1208.
    1. Doi AM, Pignatari ACC, Edmond MB, et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian national surveillance program. PloS One. 2016;11(1):e0146909.
    1. Calandra T, Roberts JA, Antonelli M, Bassetti M, Vincent JL. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care. 2016;20(1):125.
    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50.
    1. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Inten Care Med. 2014;40(10):1489–1498.
    1. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Inten Care Med. 2014;40(9):1303–1312.
    1. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9(7):e101510.
    1. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit care Med. 2008;36(7):1993–1998.
    1. Shigemura K, Osawa K, Jikimoto T, et al. Comparison of the clinical risk factors between candida albicans and candida non-albicans species for bloodstream infection. J Antibiot (Tokyo). 2014;67(4):311–314.
    1. Wu JQ, Zhu LP, Ou XT, et al. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol. 2011;49(5):552–555.
    1. Wang L, Tong Z, Wang Z, et al. Single-center retrospective study of the incidence of, and risk factors for, non-C. albicans invasive candidiasis in hospitalized patients in China. Med mycol. 2014;52(2):115–122.
    1. Arendrup MC. Update on antifungal resistance in aspergillus and candida. Clin Microbiol Infect. 2014;20(suppl 6):42–48.
    1. Chapman B, Slavin M, Marriott D, et al. Changing epidemiology of candidaemia in Australia. J Antimicrob chemother. 2017;72(4):1270.
    1. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in candida albicans and emerging Non-albicans candida species. Front Microbiol. 2016;7:2173.
    1. Tan TY, Hsu LY, Alejandria MM, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 2016;54(5):471–477.
    1. Marriott DJ, Playford EG, Chen S, et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care. 2009;13(4):R115.
    1. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. Jantimicrob chemother.2007;60(3):613–618.
    1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob agents chemother. 2005;49(9):3640–3645.
    1. Grim SA, Berger K, Teng C, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob chemother. 2012;67(3):707–714.
    1. Cui N, Wang H, Qiu H, Li R, Liu D. Impact of initial empirical antifungal agents on the outcome of critically ill patients with invasive candidiasis: analysis of the China-scan study. Int J Antimicrob Agents. 2017;50(1):74–80.
    1. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, de Pipaón MRP, Hernández-Caballero C, Lepe-Jiménez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. Jantimicrob Chemother. 2013;68(1):206–213.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever